Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $25.57 Consensus PT from Brokerages - MarketBeat
10 hours ago • Google News
Stoke Therapeutics Inc (STOK)
US$ 00%
Price Chart
Key Statistics
Market Cap
$ 1.25B
P/E Ratio
26.14
Revenue (TTM)
$ 199.89M
Volume
0
52W High
$ 24.60
52W Low
$ 5.35
Dividend Yield
0.00%
Beta
1.14
Technicals
50-Day MA
16.5632
200-Day MA
11.5534
52 Week High
24.6
52 Week Low
5.35
About STOK
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Employees
128
Headquarters
Bedford, MA
CEO
Dr. Arthur O. Tzianabos Ph.D.